NASDAQ:IRIX - IRIDEX Stock Price, Forecast & News

IRIDEX trades on the NASDAQ under the ticker symbol "IRIX."

IRIDEX Co. (NASDAQ:IRIX) issued its quarterly earnings results on Thursday, November, 7th. The medical equipment provider reported ($0.13) earnings per share (EPS) for the quarter, beating the Thomson Reuters' consensus estimate of ($0.18) by $0.05. The medical equipment provider had revenue of $10.66 million for the quarter, compared to analyst estimates of $10.08 million. IRIDEX had a negative return on equity of 37.78% and a negative net margin of 23.42%. View IRIDEX's Earnings History.

IRIDEX is scheduled to release their next quarterly earnings announcement on Tuesday, March 3rd 2020. View Earnings Estimates for IRIDEX.

IRIDEX updated its fourth quarter 2019 After-Hours earnings guidance on Monday, January, 13th. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $11.6-11.8 million, compared to the consensus revenue estimate of $10.88 million.

News stories about IRIX stock have been trending neutral this week, InfoTrie Sentiment reports. InfoTrie rates the sentiment of media coverage by analyzing more than six thousand news and blog sources. The firm ranks coverage of publicly-traded companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. IRIDEX earned a daily sentiment score of 0.4 on InfoTrie's scale. They also assigned headlines about the medical equipment provider a news buzz of 9.0 out of 10, indicating that recent media coverage is extremely likely to have an impact on the company's share price in the near term. View News Stories for IRIDEX.

IRIDEX saw a decrease in short interest in January. As of January 31st, there was short interest totalling 78,800 shares, a decrease of 12.0% from the January 15th total of 89,500 shares. Based on an average trading volume of 70,900 shares, the days-to-cover ratio is presently 1.1 days. Currently, 0.7% of the shares of the stock are short sold. View IRIDEX's Current Options Chain.

Some companies that are related to IRIDEX include Soleno Therapeutics (SLNO), Fonar (FONR), Edap Tms (EDAP), BioSig Technologies (BSGM), Second Sight Medical Products (EYES), Fc Global Realty (FCRE), electroCore (ECOR), Helius Medical Technologies (HSDT), Precision Optics (PEYE), ENDRA Life Sciences (NDRA), Digirad (DRAD), Vaso (VASO), Non-Invasive Monitoring Systems (NIMU), Reshape Lifesciences (RSLS) and Viveve Medical (VIVE).

Based on aggregate information from My MarketBeat watchlists, some companies that other IRIDEX investors own include SCYNEXIS (SCYX), NovaBay Pharmaceuticals (NBY), Agile Therapeutics (AGRX), CTI BioPharma (CTIC), Gilead Sciences (GILD), Trevena (TRVN), AbbVie (ABBV), Allena Pharmaceuticals (ALNA), Capstone Turbine (CPST) and Fate Therapeutics (FATE).

IRIDEX's stock is owned by a number of of retail and institutional investors. Top institutional shareholders include Renaissance Technologies LLC (3.43%), Isthmus Partners LLC (1.54%), Perkins Capital Management Inc. (0.39%), Gabelli Funds LLC (0.11%) and Blair William & Co. IL (0.09%). Company insiders that own IRIDEX stock include Associates & Paragon A Paragon, Robert Earle Grove, Romeo R Dizon, Scott Shuda and William M Moore. View Institutional Ownership Trends for IRIDEX.

IRIX stock was sold by a variety of institutional investors in the last quarter, including Blair William & Co. IL and Gabelli Funds LLC. View Insider Buying and Selling for IRIDEX.

IRIX stock was acquired by a variety of institutional investors in the last quarter, including Renaissance Technologies LLC, Isthmus Partners LLC and Perkins Capital Management Inc.. Company insiders that have bought IRIDEX stock in the last two years include Associates & Paragon A Paragon, Robert Earle Grove, Scott Shuda and William M Moore. View Insider Buying and Selling for IRIDEX.

Shares of IRIX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of IRIX stock can currently be purchased for approximately $3.24.

IRIDEX has a market capitalization of $44.65 million and generates $42.60 million in revenue each year. The medical equipment provider earns $-12,810,000.00 in net income (profit) each year or ($1.05) on an earnings per share basis. View Additional Information About IRIDEX.

The official website for IRIDEX is http://www.iridex.com/.

IRIDEX's mailing address is 1212 Terra Bella Avenue, Mountain View CA, 94043. The medical equipment provider can be reached via phone at 650-940-4700 or via email at [email protected]